Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is enrolling Phase 3 clinical
trials for registration in North, Central and South America and Europe.
Clevudine is already approved for HBV in South Korea and marketed by
Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128,
an oral treatment for chronic HCV infection, is in a Phase 1/2 clinical
trial in combination with Pegasys(R) plus Copegus(R) through a strategic
collaboration with Roche. Racivir, which is being developed for the
treatment of HIV in combination with other approved HIV drugs, has
completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Chief Financial Officer
Office: +1 (609) 613-4110
Pharmasset "Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995: Statements in this press release regarding
our business that are not historical facts are "forward-looking statements"
that involve risks and uncertainties, including without limitation, the
risk that the closing of the offering may not occur, the
|SOURCE Pharmasset, Inc.|
Copyright©2008 PR Newswire.
All rights reserved